Urinary Metabolic and Hemodynamic Protein Signatures in Canagliflozin Treated Patients With Diabetic Kidney Disease: Findings From CREDENCE

ABSTRACT Background Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) provide kidney protection in patients with diabetic kidney disease (DKD). There is limited knowledge about the mechanisms by which they protect the kidney. We investigated which urinary proteins and pathways are associated with progressive kidney disease and canagliflozin treatment. Materials and Methods This case–control study included patients from the CREDENCE trial. Cases and controls were defined by annual eGFR decline of ≥ 5 or < 1 mL/min/1.73 m 2 and propensity score‐matched within treatment arms. High‐throughput urinary proteomics (SomaLogic, n = 5284 aptamers) was performed at baseline and year 1. Differential abundance analysis assessed 1‐year changes between cases and controls, and between canagliflozin and placebo‐treated patients. Identified proteins were mapped to kidney biopsy single‐cell RNA sequencing (scRNA‐seq) data from patients with type 2 diabetes, with or without SGLT2i treatment to identify cell type‐specific expression. Results Of 392 included participants, 250 were randomized to canagliflozin and 142 to placebo. After 1 year, 124 proteins were changed by canagliflozin compared to placebo (92 increased and 32 decreased). Enolase 1, SLIT, NTRK Like Family Member 1, and leucine‐rich repeat containing 15 increased more than 3‐fold, while decreases were observed in alanyl aminopeptidase, discoidin domain receptor 1 and ameloblastin. Pathway analysis revealed enhanced activity of metabolic pathways. scRNA‐seq data showed increased expression of metabolic genes after SGLT2i treatment in distal tubular cells. Conclusion These findings suggest that SGLT2i administration induces a redistribution of tubular workload through compensatory sodium reabsorption in distal parts of the nephron, which may contribute to kidney‐protective effects in DKD.

Authors

Institutions

Publication Details

Journal
Diabetes Obesity and Metabolism
Published
2026-11-15
DOI
https://doi.org/10.1111/dom.71518
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Urinary Metabolic and Hemodynamic Protein Signatures in Canagliflozin Treated Patients With Diabetic Kidney Disease: Findings From CREDENCE

Michael K. Hansen, Niels Jongs, Viji Nair, Hiddo J.L. Heerspink et al.
Diabetes Obesity and Metabolism
Chronic Kidney Disease and Diabetes
article

Urinary Metabolic and Hemodynamic Protein Signatures in Canagliflozin Treated Patients With Diabetic Kidney Disease: Findings From CREDENCE

Michael K. Hansen, Niels Jongs, Viji Nair, Hiddo J.L. Heerspink, Petter Bjornstad, Edgar A. Otto, Matthias Kretzler, Adriaan A. Voors, Rajasree Menon, Wenjun Ju, Mark André de la Rambelje
article en

Abstract

ABSTRACT Background Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) provide kidney protection in patients with diabetic kidney disease (DKD). There is limited knowledge about the mechanisms by which they protect the kidney. We investigated which urinary proteins and pathways are associated with progressive kidney disease and canagliflozin treatment. Materials and Methods This case–control study included patients from the CREDENCE trial. Cases and controls were defined by annual eGFR decline of ≥ 5 or < 1 mL/min/1.73 m 2 and propensity score‐matched within treatment arms. High‐throughput urinary proteomics (SomaLogic, n = 5284 aptamers) was performed at baseline and year 1. Differential abundance analysis assessed 1‐year changes between cases and controls, and between canagliflozin and placebo‐treated patients. Identified proteins were mapped to kidney biopsy single‐cell RNA sequencing (scRNA‐seq) data from patients with type 2 diabetes, with or without SGLT2i treatment to identify cell type‐specific expression. Results Of 392 included participants, 250 were randomized to canagliflozin and 142 to placebo. After 1 year, 124 proteins were changed by canagliflozin compared to placebo (92 increased and 32 decreased). Enolase 1, SLIT, NTRK Like Family Member 1, and leucine‐rich repeat containing 15 increased more than 3‐fold, while decreases were observed in alanyl aminopeptidase, discoidin domain receptor 1 and ameloblastin. Pathway analysis revealed enhanced activity of metabolic pathways. scRNA‐seq data showed increased expression of metabolic genes after SGLT2i treatment in distal tubular cells. Conclusion These findings suggest that SGLT2i administration induces a redistribution of tubular workload through compensatory sodium reabsorption in distal parts of the nephron, which may contribute to kidney‐protective effects in DKD.

Diabetes Obesity and Metabolism
University Medical Center Groningen (NL), University of Washington (US), University of Michigan (US), Michigan Medicine (US)
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon